Modulation of drug release from hydrophilic matrices

Pharmaceutical Technology Europe

Volumn 20, Issue 9, 2008, Pages 24-32

  Tiwari, Sandip B ^a   Rajabi Siahboomi, Ali R ^a  

^a Colorcon Inc ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXCIPIENT; HYDROXYPROPYLMETHYLCELLULOSE; METHYLCELLULOSE; NIFEDIPINE; VENLAFAXINE;

ARTICLE; CONTROLLED DRUG RELEASE; DRUG MARKETING; DRUG SOLUBILITY; DRUG STABILITY; HYDROPHILICITY; MATRIX TABLET; PHYSICAL CHEMISTRY; TABLET FORMULATION; TABLET MANUFACTURE; TABLET PROPERTY; VISCOSITY;

EID: 52749091566     PISSN: 01646826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. D.A. Alderman, Int. J. Pharm. Tech. Prod. Mfr., 5, 1-9 (1984).
2. J.E. Hogan, Drug Dev. Ind. Pharm., 15, 975-999 (1989).
3. C. L. Li et al., J. Pharm. Pharmacol., 57, 533-546 (2005).
4. A.R. Rajabi-Siahboomi and M.P. Jordan, Eur. Pharm. Rev., 5, 21-23 (2000).
5. S. Siepe et al., Int. J. Pharm., 316, 14-20 (2006).
6. Colorcon, "Extended/Controlled Release" (2008). www.colorcon.com
7. US Pharmacopeia-NF Online, "USP Monographs: Hypromellose" www.uspnf.com
8. A.R. Rajabi-Siahboomi et al., Pharm. Res., 13, 376-380 (1996).
9. The Dow Chemical Company, "Methocel products", (2008). www.dow.com
10. P. Gao et al., J. Pharm. Sci., 85, 732-740 (1996).
11. I.J Hardy, W.G. Cook and C.D. Melia, Int. J. Pharm., 311, 26-32 (2006).
12. Y. Huang et al., Drug Dev. Ind. Pharm., 29, 79-88 (2003).
13. M. Levina and A.R. Rajabi-Siahboomi, J. Pharm. Sci., 93, 2746-2754 (2004).
14. K. Mitchell et al., Int. J. Pharm., 100, 165-173 (1993).
15. K. Mitchell et al., Int. J. Pharm., 66, 233-242 (1990).
16. A. Nokhodchi et al., Int. J. Pharm., 129, 21-31 (1996).
17. A. Nokhodchi et al., J. Pharm. Pharmacol., 48, 1116-1121 (1996).
18. A.R. Rajabi-Siahboomi, A. Nokhodchi and M.H. Rubinstein, Pharm. Technol. Yearbook, 32-40 (1998).
19. The Dow Chemical Company, "Using Dow excipients for controlled release of drugs in hydrophilic matrix systems", (2006). www.dow.com
20. A.V. Gothoskar et al., "Controlling the release of nifedipine (a practically insoluble drug) using hypromellose matrices", at the Controlled Release Society 33rd Annual Meeting and Exposition (Vienna, Austria, July 2006).
21. B. Abrahamsson et al., Eur. J. Pharm. Biopharm., 46, 69-75 (1998).
22. B. Abrahamsson, K. Roos and J. Sjogren, Drug Dev. Ind. Pharm., 25, 765-771 (1999).
23. S.K. Baveja, K.V. Ranga Rao and K. Padmalata Devi, Int. J. Pharm., 39, 39-45 (1987).
24. M.A. Dabbagh, Pharm. Dev. Technol., 4, 3113-324 (1999).
25. N. Vatsaraj, H. Zia and T. Needham, Drug Deliv., 9, 153-159 (2002).
26. S. Conti et al., Int. J. Pharm., 333, 136-142 (2007).
27. S. Conti et al., Int. J. Pharm., 333, 143-151 (2007).
28. P. Timmins, A.M. Delargy and J.R. Howard, Pharm. Dev. Technol., 2, 25-31 (1997).
29. Y.B. Huang et al., Int. J. Pharm., 289, 87-95 (2005).
30. P. Giunchedi et al., AAPS PharmSciTech., 1, E19 (2000).
31. S.M. Samani, H. Montaseri and A. Kazemi, Eur. J. Pharm. Biopharm., 55, 351-355 (2003).
32. S.M. Khamanga and R.B. Walker, "Comparison of method of manufacture on in vitro performance of verapamil matrix tablets", at the Controlled Release Society 32nd Annual Meeting and Exposition (Miami, FL, USA, July 2005).
33. S.A. Bravo, M.C. Lamas and C.J. Salomon, Pharm. Dev. Technol., 9, 75-83 (2004).
34. S. Li, Int. J. Pharm., 253, 13-22 (2003).
35. S. Takka, Farmaco, 58, 1051-1056 (2003).
36. S. Takka, S. Rajbhandari and A. Sakr, Eur. J. Pharm. Biopharm., 52, 75-82 (2001).
37. B.M. Al-Taani and B.M. Tashtoush, AAPS PharmSciTech., 4, E43 (2003).
38. R.C. Rowe, P.J. Sheskey and S.C. Owen (Eds.), Handbook of Pharmaceutical Excipients (Pharmaceutical Press, London, UK, 2006).
39. A. Streubel, J. Control Release, 67, 101-110 (2000).
40. J. Varshosaz, N. Tavakoli and S.A. Eram, Drug Delivery, 13, 113-119 (2006).
41. M.C. Gohel, Boll. Chim. Farm., 141, 21-28 (2002).
42. C.H. Hsiao, US Patent 4556678 (1985).
43. N.K. Ebube and A.B. Jones, Int, J. Pharm., 272, 19-27 (2004).
44. M.L. Vueba, Pharm. Dev. Technol., 11, 213-228 (2006).
45. C.S. Fuller, Polymer, 42, 9583-9592 (2001).
46. R.J. Macrac and J. Sarah, WO 97/18814 (1997).
47. L. Yang and R. Fassishi, J. Control Rel., 44 135-140 (1997).
48. L. Yang and R. Fassihi, Int. J. Pharm., 155, 219-229 (1997).
49. G. Gusler, US Patent 6723340 (2004).
50. A.R. Rajabi-Siahboomi et al., US Patent application 20070048377 (2007).
51. J.R. Howard and P. Timinis, US Patent 4792452 (1998).
52. A.S. Tatavarti et al., J. Pharm. Sci., 93, 2319-2331 (2004).
53. A.S. Tatavarti and S.W. Hoag, J. Pharm. Sci., 95, 1459-1468 (2006).
54. V.M. Rao, K. Engh and Y. Qiu, Int, J. Pharm., 252, 81-86 (2003).
55. The Dow Chemical Company "POLYOX products" (2008). www.dow.com
56. C.J. Kim, J. Pharm. Sci., 84, 303-306 (1995).
57. V.D. Dias et al., "Modulation of drug release from hypromellose (HPMC) matrices: suppression of the initial burst effect", at The American Association of Pharmaceutical Scientists Annual Meeting and Exposition (San Antonio, TX, USA, 2006).
58. C.D. Melia, Crit. Rev. Ther. Drug Carrier Syst., 8, 395-421 (1991).
59. B.B. Lohray and S.B. Tiwari, WO/2005/123134 (2005).
60. S.B. Tiwari et al., AAPS PharmSciTech., 4, E31 (2003).
61. L. Ochoa et al., J. Pharm. Pharm. Sci., 8, 132-140 (2005).